Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
Trial details
- Registry ID
- NCT06282458
- Phase
- Phase 2
The FDA approved Semaglutide (Wegovy) on 5 Dec 2017.
Drug identity checked against registry records
Also recorded as Wegovy
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight MgmtNCT06282458 | VERU | Phase 2 | Completed | 2025-04-11Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2017-12-05Day | Semaglutide | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA209637", "applicant_as_listed_by_fda": "NOVO", "brand_names": ["OZEMPIC"], "active_ingredients": ["SEMAGLUTIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20171205", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |